Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 24, 2006BloodOpen Access

Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJohn M. PagelEppendorf (Germany)YLYukang LinGuangzhou University of Chinese MedicineNHNathan HedinAmgen (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pagel et al. (2006) studied this question.

synapsesocial.com/papers/6a71cb0e26a7f98052ddfa93https://doi.org/10.1182/blood-2005-11-4327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile2000 · 89 citations
  2. 2Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.1998 · 182 citations
  3. 3Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma2004 · 154 citations
  4. 4A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts2001 · 149 citations